

Cite this: *RSC Chem. Biol.*, 2025, 6, 1148

An iridium(III) 3-chloro-6-thio-1,2,4,5-tetrazine complex for cysteine conjugation, bioimaging and photoactivated therapy†

Lili Huang,^a Justin Shum,^{ab} Lawrence Cho-Cheung Lee,^{id a} Guang-Xi Xu,^a Peter Kam-Keung Leung^{ac} and Kenneth Kam-Wing Lo^{id *ac}

Photoactivatable systems have received considerable attention in the development of diagnostics and therapeutics due to their noninvasive nature and precise spatiotemporal control. Of particular interest is the 3,6-dithio-1,2,4,5-tetrazine (*S,S*-tetrazine) unit, which can not only act as a photolabile protecting group for constructing photoactivatable systems but also as a bioorthogonal scaffold that enables the inverse electron-demand Diels–Alder (IEDDA) cycloaddition reaction with strained alkynes. In this study, we designed and synthesised a cyclometallated iridium(III) complex modified with a 3-chloro-6-thio-1,2,4,5-tetrazine moiety (**1**) for cysteine conjugation. The complex was conjugated with an integrin-targeting peptide c(RGDfC) to afford a tumour-targeting conjugate (**1-RGD**) for bioimaging and photoactivated therapy. An RGD-free analogue (**2**) was also prepared for comparison studies. Unlike common iridium(III) complexes, excitation of conjugate **1-RGD** and complex **2** resulted in weak emission and negligible singlet oxygen (¹O₂) generation due to the quenching effect of the tetrazine unit. Upon continuous light irradiation, the *S,S*-tetrazine moiety in conjugate **1-RGD** and complex **2** underwent efficient photodissociation, yielding thiocyanate (**3**) and amide (**4**) complexes as photoproducts with increased emission intensities and enhanced ¹O₂ generation efficiencies. Interestingly, the IEDDA cycloaddition reaction of the *S,S*-tetrazine-containing conjugate **1-RGD** and complex **2** with (1*R*,8*S*,9*S*)-bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN-OH) led to significant emission enhancement. Notably, conjugate **1-RGD** showed higher cellular uptake and (photo)cytotoxicity (IC_{50,dark} = 26 μM, IC_{50,light} = 0.08 μM) in U87-MG cells, which overexpress integrin, compared to MCF-7 (IC_{50,dark} = 52 μM, IC_{50,light} = 0.22 μM) and HEK293 cells (IC_{50,dark} > 50 μM, IC_{50,light} = 1.3 μM) with lower integrin levels. This work will contribute to the development of photoactivatable transition metal complexes for cancer-targeted imaging and therapy.

Received 20th December 2024,
Accepted 6th May 2025

DOI: 10.1039/d4cb00316k

rsc.li/rsc-chembio

Introduction

In the past few decades, significant advancements have been made in the development of therapeutic agents for the effective treatment of various human diseases.^{1–3} However, challenges remain in achieving effective therapy at specific disease sites due to the limited selectivity of existing therapeutics, which can lead to potential side effects on healthy tissues.^{4,5} To overcome this hurdle, different therapeutic agents have been developed

that are responsive to endogenous (*e.g.*, pH, enzymes and redox reactions) and exogenous stimuli (*e.g.*, light, ionizing irradiation and magnetic fields).^{6,7} Photoactivatable systems that undergo photochemical reactions and generate radical species or release molecules of interest upon light irradiation have gained significant attention.^{8,9} By adjusting parameters such as irradiation wavelength, intensity and duration, these light-based approaches offer precise spatiotemporal control, enabling efficient accumulation of therapeutic agents at the target site and potent therapeutic effects.¹⁰


With their rich photophysical and photochemical properties, transition metal complexes have been widely utilised for the construction of photoactivatable therapeutics.^{11–14} In particular, transition metal complexes that can undergo photoactivated chemotherapy (PACT) are of significant interest because they are noncytotoxic in the dark but become highly (photo)cytotoxic after light irradiation due to photoinduced ligand dissociation.^{15,16} For example, ruthenium(II) polypyridine

^a Department of Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, P. R. China. E-mail: bhkenlo@cityu.edu.hk^b Laboratory for Synthetic Chemistry and Chemical Biology Limited, Units 1503-1511, 15/F, Building 17 W, Hong Kong Science Park, New Territories, Hong Kong, P. R. China^c State Key Laboratory of Terahertz and Millimetre Waves, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, P. R. China† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4cb00316k>


complexes with distorted octahedral geometry can undergo phototriggered ligand loss with significantly enhanced cytotoxicity upon light irradiation due to the generation of solvent-substituted photoproducts that can covalently bind to DNA.¹⁷ Another example used a sterically hindered ruthenium(II) complex conjugated to a nicotinamide phosphoribosyltransferase inhibitor, which undergoes photodissociation upon light irradiation to induce cytotoxic effects.¹⁸ Apart from the release of ligands from the coordination sphere of the metal centre, the attachment of organic photolabile protecting groups (PPGs) to ligands is another effective strategy to induce controllable cytotoxicity. Previously, we have developed iridium(III) complexes modified with a poly(ethylene glycol) (PEG) chain using a 2-nitrobenzyl moiety as a photosensitive linker.¹⁹ Upon light irradiation, the departure of the biocompatible PEG moiety leads to enhanced cytotoxicity of the resultant complex.

1,2,4,5-Tetrazine, known for its exceptional ability to quench various luminophores through Förster resonance energy transfer^{20,21} or photoinduced electron transfer,²² can serve as a versatile bioorthogonal scaffold that enables rapid and selective inverse electron-demand Diels–Alder (IEDDA) cycloaddition reactions with strained alkynes.²³ Interestingly, studies on 3,6-dithio-1,2,4,5-tetrazine (*S,S*-tetrazine) derivatives have shown their potential as useful phototriggers, allowing the investigation of early events in peptide/protein-folding.^{24,25} These *S,S*-tetrazines display an additional absorption band centred at 410 nm compared to traditional tetrazines, which can be attributed to an $n \rightarrow \pi^*$ transition or charge-transfer involving the sulfur atoms, leading to photodissociation upon visible-light activation.²⁶ The photodissociation process occurs rapidly in the picosecond timescale, yielding inert photoproducts (thiocyanates and dinitrogen) with a high yield (Scheme 1).²⁵

A previous study has revealed that 3-chloro-6-thio-1,2,4,5-tetrazine (*Cl,S*-tetrazine) can selectively label cysteine residues in proteins to yield conjugates bearing an *S,S*-tetrazine moiety.²⁷ It is anticipated that the integration of a *Cl,S*-tetrazine moiety into luminescent iridium(III) polypyridine complexes can afford a new class of labelling reagents for cysteine residues, leading to the construction of photoactivatable bioconjugates. In this study, we designed and synthesised an iridium(III) *Cl,S*-tetrazine complex, $[\text{Ir}(\text{pqe})_2(\text{bpy-CONH-S-Tz-Cl})](\text{PF}_6)$ (Hpqe = 2-phenylquinoline-4-carboxylic acid methyl ester; bpy-CONH-S-Tz-Cl = 4-(*S*-(6-chloro-1,2,4,5-tetrazin-3-yl)-*N*-mercaptoethylaminocarbonyl)-4'-methyl-2,2'-bipyridine) (**1**) (Scheme 2). Its *S,S*-tetrazine-containing counterpart $[\text{Ir}(\text{pqe})_2(\text{bpy-CONH-S-Tz-S-Et})](\text{PF}_6)$ (bpy-CONH-S-Tz-S-Et = 4-(*S*-(6-ethylthio-1,2,4,5-tetrazin-3-yl)-*N*-mercaptoethylaminocarbonyl)-4'-methyl-2,2'-bipyridine) (**2**) and the *S,S*-tetrazine-free analogues, $[\text{Ir}(\text{pqe})_2(\text{bpy-CONH-SCN})](\text{PF}_6)$ (bpy-CONH-SCN = 4-(*N*-(thiocyanatoethyl)aminocarbonyl)-4'-methyl-2,2'-bipyridine) (**3**) and $[\text{Ir}(\text{pqe})_2(\text{bpy-CONH}_2)](\text{PF}_6)$ (bpy-CONH₂ = 4-aminocarbonyl-4'-methyl-2,2'-bipyridine) (**4**) were also prepared for comparison studies. All the complexes were characterised by high-resolution ESI-MS, NMR and IR spectroscopy. Detailed synthetic procedures and characterisation data are included in the ESI† Upon photoexcitation, the tetrazine complexes **1** and **2** exhibited substantially weaker emission intensities and lower singlet oxygen (¹O₂) generation efficiencies compared to



Scheme 1 Photodissociation reaction of an *S,S*-tetrazine into thiocyanates and dinitrogen.



Scheme 2 Structures of complexes **1–4**.

complexes **3** and **4** due to the quenching effect of the tetrazine unit. Notably, upon continuous light irradiation, the *S,S*-tetrazine moiety in complex **2** underwent efficient dissociation, yielding the thiocyanate and amide complexes **3** and **4** as the photoproducts with increased emission intensities and enhanced ¹O₂ photogeneration efficiencies. Additionally, complex **2** can undergo IEDDA cycloaddition reaction with (1*R*,8*S*,9*S*)-bicyclo[6.1.0]non-4-yn-9-ylmethanol (BCN-OH), leading to significant emission enhancement. The photosensitivity of *S,S*-tetrazine motivated us to utilise complex **1** to modify the cysteine residue of an integrin-binding peptide c(RGDfC), affording an *S,S*-tetrazine-containing peptide conjugate $[\text{Ir}(\text{pqe})_2(\text{bpy-CONH-S-Tz-S-RGD})](\text{CF}_3\text{COO})$ (**1-RGD**) that showed intriguing photoactivatable characteristics and tumour-targeting capabilities. Remarkably, the conjugate displayed efficient cellular uptake and potent photocytotoxicity towards integrin-overexpressing human glioblastoma U87-MG cells.

Results and discussion

Photophysical properties

The electronic absorption data and spectra of complexes **1–4** are presented in Table S1 and Fig. S1 (ESI†). The complexes displayed intense spin-allowed intraligand (¹IL) ($\pi \rightarrow \pi^*$) (N^N/pqe) absorption (*ca.* 255–385 nm) and weaker spin-allowed metal-to-ligand charge-transfer (¹MLCT) ($d\pi(\text{Ir}) \rightarrow \pi^*(N^N/\text{pqe})$) absorption bands/shoulders (*ca.* 390–475 nm).^{28,29} The weak absorption tail beyond *ca.* 550 nm is assigned to spin-forbidden ³MLCT ($d\pi(\text{Ir}) \rightarrow \pi^*(N^N/\text{pqe})$) transitions. Additionally, a weak absorption band at around 510–530 nm was observed, which is ascribed to the $n \rightarrow \pi^*$ transition of the tetrazine unit (Fig. S1, ESI†). Upon photoexcitation, complexes **1–4** exhibited a structureless emission band with positive solvatochromism in fluid solutions at 298 K (Table 1 and Fig. S2, ESI†). The emission maxima of the complexes showed significant blueshifts when the samples were cooled to 77 K,



Table 1 Photophysical data of complexes 1–4 and conjugate 1-RGD

Complex/conjugate	Medium (T/K)	λ_{em}^a/nm	Φ_{em}^b	$\tau_o^c/\mu s$
1	CH ₃ CN (298)	632	0.003	0.68
	Buffer ^d (298)	650	0.002	0.23
	Glass ^e (77)	596, 646 sh		4.25
2	CH ₃ CN (298)	631	0.004	0.60
	Buffer ^d (298)	650	0.002	0.18
	Glass ^e (77)	594, 644 sh		4.38
3	CH ₃ CN (298)	634	0.14	0.69
	Buffer ^d (298)	648	0.02	0.35
	Glass ^e (77)	598, 645 sh		4.79
4	CH ₃ CN (298)	631	0.15	0.67
	Buffer ^d (298)	648	0.02	0.34
	Glass ^e (77)	597, 647 sh		4.23
1-RGD	CH ₃ CN (298)	631	0.003	0.58
	Buffer ^d (298)	648	0.001	0.19
	Glass ^e (77)	596, 644 sh		4.14

^a $\lambda_{ex} = 350$ nm, ^b [Ru(bpy)₃]Cl₂ was used as a reference ($\Phi_{em} = 0.040$ in aerated H₂O, $\lambda_{ex} = 455$ nm).³⁰ ^c The lifetimes were measured at the emission maxima ($\lambda_{ex} = 375$ nm). ^d Potassium phosphate buffer (50 mM, pH 7.4)/CH₃CN (1:1, v/v). ^e EtOH/MeOH (4:1, v/v). sh: shoulder

suggesting a ³MLCT ($d\pi(Ir) \rightarrow \pi^*(N^N/pqee)$) excited state (Fig. S2, ESI[†]). Due to the efficient emission quenching property of the tetrazine unit, complexes 1 and 2 showed much lower emission quantum yields ($\Phi_{em} \leq 0.004$) than complexes 3 and 4 ($\Phi_{em} \geq 0.14$) (Table 1). The ¹O₂ quantum yields (Φ_{Δ}) of complexes 1–4 were evaluated in aerated CH₃CN using 1,3-diphenylisobenzofuran as the ¹O₂ scavenger (Table S2, ESI[†]). The Φ_{Δ} values of the tetrazine complexes 1 and 2 were determined to be 0.55 and 0.60, respectively, which are lower than those of the tetrazine-free complexes 3 and 4 (0.81 and 0.79, respectively). These results indicate that the tetrazine unit can not only quench the emission of the complexes but also suppress their ¹O₂ photogeneration efficiencies.




Fig. 1 (a) HPLC chromatograms of complex 2 (10 μM) in aerated PBS/DMSO (9:1, v/v) treated before (black) or after (red) photoirradiation. ESI-mass spectra of the photodissociation products collected at (b) $t_R = 16.53$ min and (c) $t_R = 16.05$ min of complex 2 (10 μM) in aerated PBS/DMSO (9:1, v/v) upon photoirradiation. (d) Emission spectra of complex 2 (10 μM) in aerated PBS/DMSO (9:1, v/v) treated before (black) or after (red) photoirradiation. Photoirradiation conditions for all experiments were carried out at 450 nm (10 mW cm⁻²) for 20 min at 298 K.



Scheme 3 Photodissociation reaction of the *S,S*-tetrazine moiety in complex 2.

Photoactivatable properties and phosphorogenic response

The photodissociation of the *S,S*-tetrazine moiety in complex 2 in phosphate-buffered saline (PBS)/DMSO (9:1, v/v) upon photoirradiation at 450 nm (10 mW cm⁻²) for 20 min was monitored by reverse-phase high-performance liquid chromatography (RP-HPLC). Notably, two new peaks at $t_R = 16.53$ and 16.05 min in the HPLC spectra were detected (Fig. 1a) after the photoreaction. ESI-MS analyses revealed that the photoreleased products were the thiocyanate complex 3 and amide complex 4 (which appears to be a photodecomposed/hydrolysed product), respectively (Scheme 3 and Fig. 1b and c). Impressively, the photodissociation of the *S,S*-tetrazine unit led to a significant increase in the emission intensity ($I/I_o = 10.7$) and lifetime ($\tau = 0.29$ μs) of the solution (Table 2 and Fig. 1d). Due to the presence of a tetrazine moiety, complex 2 was also expected to undergo IEDDA cycloaddition reaction with BCN-OH to afford 2-BCN (Scheme 4). The phosphorogenic response of complex 2 towards BCN-OH was investigated. The IEDDA reaction of complex 2 (10 μM) with excess BCN-OH (500 μM) in PBS/DMSO (9:1, v/v) at 298 K produced a non-quenching pyridazine product (Fig. S3, ESI[†]), leading to significant emission enhancement and lifetime extension ($I/I_o = 38.9$; $\tau = 0.37$ μs; Table 2).

Construction of an integrin-targeting peptide conjugate bearing an *S,S*-tetrazine moiety


Having examined that the iridium(III) *S,S*-tetrazine complex displayed remarkable phosphorogenic response upon both photodissociation and bioorthogonal reactions, we used complex 1 as a labelling reagent for the construction of *S,S*-tetrazine-containing peptide conjugates that can be applied for

Table 2 Emission enhancement factors (I/I_o) and lifetimes (τ) of complex 2 and conjugate 1-RGD (10 μM) upon photoirradiation at 450 nm (10 mW cm⁻²) in aerated PBS/DMSO (9:1, v/v) for 20 min or incubation with BCN-OH (500 μM) in aerated PBS/DMSO (9:1, v/v) in the dark for 16 h. The emission lifetimes of complex 2 and conjugate 1-RGD alone under the same conditions could not be determined with accuracy due to very weak emission

Complex/conjugate	Complex/conjugate + $h\nu$			Complex/conjugate + BCN-OH		
	λ_{em}^a/nm	I/I_o^b	$\tau^c/\mu s$	λ_{em}^a/nm	I/I_o^d	$\tau^e/\mu s$
2	648	10.7	0.29	631	38.9	0.37
1-RGD	648	9.9	0.26	632	31.9	0.33


^a $\lambda_{ex} = 350$ nm. ^b I_o and I are the emission intensities of complex 2 or conjugate 1-RGD (10 μM) before and after photoirradiation at 450 nm (10 mW cm⁻²) for 20 min, respectively. ^c The lifetimes were measured at the emission maxima ($\lambda_{ex} = 375$ nm). ^d I_o and I are the emission intensities of complex 2 or conjugate 1-RGD (10 μM) in the absence and presence of BCN-OH (500 μM, 16 h), respectively.





Scheme 4 The IEDDA cycloaddition reaction of complex **2** with BCN-OH.

tumour-targeted phototherapy. Integrins, consisting of α - and β -subunits, play an important role in cell adhesion mediation and signalling.³¹ The RGD sequence, as the minimal integrin-binding motif, has been widely applied in imaging and tumour-targeted therapy due to its high binding affinity with integrins.^{32,33} A cyclic RGD peptide containing a cysteine c(RGDfC) was selected for conjugation with complex **1** to afford the peptide conjugate **1-RGD** (Scheme 5) that is expected to exhibit enhanced accumulation and photoactivatable therapeutic effects in cancer cells overexpressing integrin $\alpha_v\beta_3$. The reactivity of complex **1** (25 μM) towards c(RGDfC) (25 μM) was examined in acetate buffer (50 mM, pH 6.0)/DMF (9:1, v/v, 1 mL) containing tris(2-carboxyethyl)phosphine (TCEP) (100 μM) at 37 $^\circ\text{C}$. After incubation for 4 h, HPLC analyses revealed that almost all the complex was transformed into the conjugation product **1-RGD**, with a conversion yield of > 95% (Fig. S4, ESI[†]). Conjugate **1-RGD** was purified by semi-preparative RP-HPLC and the purified product was characterised by HPLC and ESI-MS (Fig. S5, ESI[†]). Upon excitation, it showed weak emission and low $^1\text{O}_2$ generation efficiency due to the presence of the *S,S*-tetrazine unit (Table 1 and Table S2, ESI[†]). The photodissociation reaction of the *S,S*-tetrazine moiety in conjugate **1-RGD** was examined by steady-state irradiation at 450 nm at 298 K; the reaction was found to complete in 20 min, yielding the thiocyanate (complex **3**) and amide (complex **4**) photoproducts, as indicated by HPLC and ESI-MS analyses (Fig. 2a–c). Interestingly, the sample solution displayed emission enhancement of 9.9 fold after photoirradiation (Fig. 2d). Additionally, conjugate **1-RGD** exhibited substantial emission enhancement and lifetime extension ($I/I_0 = 31.9$, $\tau = 0.33 \mu\text{s}$; Table 2 and Fig. S6, ESI[†]) upon reacting with BCN-OH. These results indicate that complex **2** and conjugate **1-RGD** bearing an *S,S*-tetrazine moiety can serve as efficient photoactivatable reagents and phosphorogenic bioorthogonal probes.



Scheme 5 Conjugation of complex **1** with peptide c(RGDfC).

Cellular studies

The higher expression of integrins in cancer cells contributes to tumour progression and metastasis by promoting tumour cell proliferation, migration and invasion.³⁴ To examine the targeting efficiency of conjugate **1-RGD** towards integrin-overexpressing cancer cell lines, cancerous brain (U87-MG; high integrin $\alpha_v\beta_3$ expression), breast (MCF-7; low integrin $\alpha_v\beta_3$ expression) and normal kidney (HEK293; low integrin $\alpha_v\beta_3$ expression) cells were used as model cell lines.^{35–38} The cellular uptake of conjugate **1-RGD** and complexes **2–4** was determined by ICP-MS and the results are listed in Table S3 (ESI[†]). Conjugate **1-RGD** showed higher accumulation in U87-MG cells (0.70 fmol) than in MCF-7 and HEK293 cells (0.32 and 0.032 fmol, respectively). Interestingly, pretreatment of U87-MG cells with free RGD peptide (50 μM , 30 min) substantially inhibited the uptake of conjugate **1-RGD** (0.34 fmol) while only exerting a slight effect in MCF-7 and HEK293 cells (0.25 and 0.030 fmol, respectively). The reduced uptake for conjugate **1-RGD** is attributed to the competitive binding with free RGD peptide to the integrin binding sites, indicative of the specificity of the conjugate towards integrin. Noteworthy, complexes **2–4** also displayed higher uptake towards U87-MG and MCF-7 cells (1.1–2.5 fmol) and much lower accumulation in HEK293 cells (0.25–0.77 fmol). However, the cellular internalisation of these complexes was not influenced by the preincubation of the cells with free RGD, indicative of no integrin binding specificity.

Based on the results, it appears that conjugate **1-RGD** was internalised by cells through an integrin-mediated mechanism, particularly in cell lines that overexpress integrins, such as U87-MG cells. The cellular uptake mechanism was further investigated using various inhibitors. Upon treating U87-MG cells with the conjugate at low temperature (4 $^\circ\text{C}$), the amount of




Fig. 2 (a) HPLC chromatograms of conjugate **1-RGD** (10 μM) in PBS/DMSO (9:1, v/v) treated before (black) or after (red) photoirradiation. ESI-mass spectra of the photodissociation products collected at (b) $t_{\text{R}} = 16.45$ min and (c) $t_{\text{R}} = 15.99$ min of conjugate **1-RGD** (10 μM) in PBS/DMSO (9:1, v/v) upon photoirradiation. (d) Emission spectra of conjugate **1-RGD** (10 μM) in PBS/DMSO (9:1, v/v) treated before (black) or after (red) photoirradiation. Photoirradiation conditions for all experiments were carried out at 450 nm (10 mW cm^{-2}) for 20 min at 298 K.



intracellular iridium significantly decreased compared to cells incubated at 37 °C (Fig. S7, ESI†). However, the internalisation of the conjugate remained unaffected by pretreatment with a cation transporter inhibitor (tetraethylammonium chloride). Preincubation of the cells with metabolic inhibitors (2-deoxy-D-glucose and oligomycin) or endocytosis inhibitors (ammonium chloride or chloroquine) also substantially reduced the cellular uptake efficiency of the conjugate. These results collectively indicate that conjugate **1-RGD** was taken up by cells *via* an energy-dependent endocytic pathway.

To further examine the specificity of conjugate **1-RGD** towards integrin $\alpha_v\beta_3$, cells were preincubated without or with free RGD, treated with the conjugate and exposed to steady-state irradiation. As revealed by laser-scanning confocal microscopy (LSCM), the intracellular emission intensity significantly decreased in U87-MG and MCF-7 cells pretreated with the free RGD peptide, while no noticeable changes were observed for HEK293 cells pretreated with or without the RGD peptide (Fig. 3). Notably, preincubation with the RGD peptide did not reduce the emission intensity of complex **2** towards any of the three cell lines (Fig. S8, ESI†), which further supports the integrin-mediated cellular uptake of conjugate **1-RGD**. The phosphorogenic property of conjugate **1-RGD** in live cells was also investigated by LSCM. Significant emission enhancement was observed for U87-MG and MCF-7 cells that were treated with the conjugate and subsequently photoirradiated, compared to the cells treated with the conjugate under dark conditions (Fig. 4). The emission enhancement is attributed to the photodissociation of the *S,S*-tetrazine moiety in conjugate **1-RGD** within the cells. In contrast, only minimal emission changes were observed for HEK293 cells treated with conjugate **1-RGD** under both dark and light conditions, probably due to limited cellular uptake of the conjugate as a result of the lower integrin expression levels of the cells. This is further supported by flow cytometric measurements, which showed higher intracellular emission enhancement for U87-MG and MCF-7 cells treated with conjugate **1-RGD** after light irradiation compared




Fig. 4 LSCM images of U87-MG, MCF-7 and HEK293 cells incubated with conjugate **1-RGD** (5 μM , 4 h; λ_{ex} = 405 nm, λ_{em} = 600–700 nm) without (upper) or with (lower) continuous photoirradiation at 450 nm (10 mW cm^{-2}) for 20 min. Scale bar = 20 μm .

to HEK293 cells (Fig. S9, ESI†). Additionally, ESI-MS analyses of U87-MG cell lysates indicate that the conjugate was transformed into the thiocyanate and amide products after photoirradiation (Fig. S10, ESI†). Similar emission enhancement was observed for U87-MG and MCF-7 cells treated with the RGD-free complex **2** while substantially lower emission enhancement was observed in HEK293 cells (Fig. S11, ESI†). The intracellular localisation of conjugate **1-RGD** and complexes **2–4** was investigated by LSCM. The phosphorogenic IEDDA reaction was utilised to study the intracellular localisation of conjugate **1-RGD** and complex **2** due to the intrinsically weak emission. The U87-MG cells were first treated with conjugate **1-RGD** or complex **2** (5 μM , 4 h), followed by incubation of BCN-OH (250 μM , 4 h) and MitoTracker Deep Red (100 nM, 20 min). LSCM images revealed that the luminescent products were specifically localised in the mitochondria with Pearson's correlation coefficients (PCC's) of 0.96 and 0.97, respectively (Fig. S12, ESI†). The cellular localisation of conjugate **1-RGD** and complex **2** after photoirradiation was also studied. Incubation of U87-MG cells with conjugate **1-RGD** or complex **2** (5 μM , 4 h), followed by photoirradiation at 450 nm (10 mW cm^{-2}) for 20 min and then co-staining with MitoTracker Deep Red (100 nM, 20 min), gave rise to substantial image overlap, with PCC values of 0.92 and 0.96, respectively (Fig. 5). The intracellular localisation of their photoproducts was examined by co-staining experiments involving complexes **3** and **4** (5 μM , 4 h), which showed significant mitochondrial accumulation (PCCs = 0.96 and 0.97, respectively) (Fig. 5). The high mitochondria specificity of the conjugate and complexes can be attributed to their high lipophilicity and monocationic charge.^{39,40}

Mitochondria play vital roles in cellular energy production, maintaining calcium levels and regulating programmed cell death within the cells.^{41,42} Given the high mitochondria-targeting ability of conjugate **1-RGD** and complexes **2–4**, their (photo)cytotoxicity towards cancerous (U87-MG and MCF-7) and normal (HEK293) cells was evaluated using the MTT assay. Notably, conjugate **1-RGD** exhibited higher dark cytotoxicity towards U87-MG cells ($\text{IC}_{50,\text{dark}} = 26 \mu\text{M}$) but no dark cytotoxicity towards MCF-7 and




Fig. 3 LSCM images of live U87-MG, MCF-7 and HEK293 cells pretreated without (upper) or with (lower) RGD peptide (50 μM , 30 min), incubated with conjugate **1-RGD** (5 μM , 4 h; λ_{ex} = 405 nm, λ_{em} = 600–700 nm) and followed by continuous photoirradiation at 450 nm (10 mW cm^{-2}) for 20 min. Scale bar = 20 μm .






Fig. 5 LSCM images of live U87-MG cells incubated with conjugate **1-RGD** or complex **2** ($5 \mu\text{M}$, 4 h; $\lambda_{\text{ex}} = 405 \text{ nm}$, $\lambda_{\text{em}} = 600\text{--}700 \text{ nm}$) and photoirradiated at 450 nm (10 mW cm^{-2}) for 20 min or incubated with complexes **3** or **4** ($5 \mu\text{M}$, 4 h; $\lambda_{\text{ex}} = 405 \text{ nm}$, $\lambda_{\text{em}} = 600\text{--}700 \text{ nm}$) in the dark and then treated with MitoTracker Deep Red (100 nM , 20 min; $\lambda_{\text{ex}} = 635 \text{ nm}$, $\lambda_{\text{em}} = 650\text{--}680 \text{ nm}$). Scale bar = $20 \mu\text{m}$. PCC = 0.92 (**1-RGD**); 0.96 (**2**); 0.96 (**3**) and 0.97 (**4**).

HEK293 cells ($\text{IC}_{50,\text{dark}} > 50 \mu\text{M}$) (Table 3), which is consistent with its cellular uptake efficiencies (Table S3, ESI[†]) and integrin-targeting properties. Additionally, the conjugate showed the highest photocytotoxicity towards U87-MG cells ($\text{IC}_{50,\text{light}} = 0.08 \mu\text{M}$) with a photocytotoxicity index (PI) value of 325 (Table 3), indicating the excellent targeting capability towards cancerous cells with integrin $\alpha_v\beta_3$ overexpression. Conjugate **1-RGD** also displayed high photocytotoxic activity towards cancerous MCF-7 cells ($\text{IC}_{50,\text{light}} = 0.22 \mu\text{M}$; PI = 236) with much lower photocytotoxicity towards normal HEK293 cells ($\text{IC}_{50,\text{light}} = 1.3 \mu\text{M}$; PI > 38). Complexes **2–4**, which did not exhibit any integrin-targeting behaviour, showed high dark cytotoxicity ($\text{IC}_{50,\text{dark}} = 2.5\text{--}15 \mu\text{M}$) and increased photocytotoxicity upon light irradiation ($\text{IC}_{50,\text{light}} = 0.02\text{--}0.10 \mu\text{M}$) towards all the cell lines. Therefore, it can be inferred that the excellent photoinduced cytotoxicity of conjugate **1-RGD** is attributed to its targeting properties towards integrin-overexpressing cancer cells, the release of highly cytotoxic photoproducts (complexes **3** and **4**) and subsequent enhanced $^1\text{O}_2$ photosensitisation




Fig. 6 LSCM images of (a) MMP, (b) plasma membrane, (c) nuclear morphology, or (d) caspase-3/7 activity of U87-MG cells upon pretreatment with conjugate **1-RGD** ($5 \mu\text{M}$, 4 h) without (upper) or with (lower) light irradiation at 450 nm (10 mW cm^{-2}) for 20 min. All the samples were stained with rhodamine 123 ($5 \mu\text{M}$, 15 min; $\lambda_{\text{ex}} = 488 \text{ nm}$, $\lambda_{\text{em}} = 500\text{--}550 \text{ nm}$), CellMask Deep Red ($5 \mu\text{M}$, 15 min; $\lambda_{\text{ex}} = 635 \text{ nm}$, $\lambda_{\text{em}} = 650\text{--}700 \text{ nm}$), Hoechst 33342 ($5 \mu\text{M}$, 15 min; $\lambda_{\text{ex}} = 405 \text{ nm}$, $\lambda_{\text{em}} = 415\text{--}495 \text{ nm}$), or CellEvent Caspase-3/7 Red ($20 \mu\text{L}$, 1:100, 1 h; $\lambda_{\text{ex}} = 590 \text{ nm}$, $\lambda_{\text{em}} = 610\text{--}630 \text{ nm}$) prior to microscope imaging. Scale bar = $20 \mu\text{m}$. (e) Flow cytometric analysis of U87-MG cells pretreated with conjugate **1-RGD** ($1 \mu\text{M}$, 4 h) without or with continuous photoirradiation at 450 nm (10 mW cm^{-2}) for 20 min, followed by staining with Alexa Fluor 647-Annexin V conjugate ($5 \mu\text{L}$, 15 min; $\lambda_{\text{ex}} = 638 \text{ nm}$) and propidium iodide ($2 \mu\text{L}$, $100 \mu\text{g mL}^{-1}$, 15 min; $\lambda_{\text{ex}} = 561 \text{ nm}$).

effect upon photoirradiation. Calcein-AM and propidium iodide double staining assay was used to further investigate the therapeutic efficacy of conjugate **1-RGD** towards U87-MG cells (Fig. S13, ESI[†]). Cells treated with conjugate **1-RGD** exhibited intense fluorescence from Calcein-AM with no emission from propidium iodide. After light irradiation, the green emission from Calcein-AM diminished, while strong red emission from the propidium dye was detected for the **1-RGD**-treated cells. This observation confirms the biocompatibility of the conjugate under dark conditions and highlights its potent cytotoxic activity upon light activation.

Based on the impressive cancer cell selectivity and photoactivatable property of conjugate **1-RGD**, the photoinduced cell death pathway was further examined. LSCM images revealed that U87-MG cells treated with conjugate **1-RGD** and reactive oxygen species (ROS) indicator CM-H₂DCFDA displayed strong emission under light conditions compared to cells under dark treatment, indicative of the effective intracellular ROS

Table 3 (Photo)cytotoxicity of conjugate **1-RGD** and complexes **2–4** towards U87-MG, MCF-7 and HEK293 cells. The cells were first incubated with the conjugate or complexes in the dark for 4 h, then incubated in the dark or irradiated at 450 nm (10 mW cm^{-2}) for 20 min and kept in the dark for 16 h. PI is the ratio of $\text{IC}_{50,\text{dark}}/\text{IC}_{50,\text{light}}$

Complex/conjugate	U87-MG			MCF-7			HEK293		
	$\text{IC}_{50,\text{dark}}/\mu\text{M}$	$\text{IC}_{50,\text{light}}/\mu\text{M}$	PI	$\text{IC}_{50,\text{dark}}/\mu\text{M}$	$\text{IC}_{50,\text{light}}/\mu\text{M}$	PI	$\text{IC}_{50,\text{dark}}/\mu\text{M}$	$\text{IC}_{50,\text{light}}/\mu\text{M}$	PI
1-RGD	26 ± 1	0.08 ± 0.01	325	52 ± 1	0.22 ± 0.01	236	> 50	1.3 ± 0.1	> 38
2	11 ± 1	0.08 ± 0.01	138	15 ± 1	0.10 ± 0.01	150	12 ± 1	0.09 ± 0.01	133
3	2.7 ± 0.1	0.02 ± 0.01	135	2.5 ± 0.1	0.02 ± 0.01	125	3.5 ± 0.2	0.04 ± 0.01	88
4	4.1 ± 0.2	0.04 ± 0.01	103	4.2 ± 0.1	0.04 ± 0.01	105	5.0 ± 0.1	0.05 ± 0.01	100



generation by the conjugate upon photoactivation (Fig. S14, ESI†). The mitochondrial membrane potential (MMP) was characterised by staining the cells with rhodamine 123 after incubation of conjugate **1-RGD** without or with light irradiation. Intense emission was detected for cells under the dark condition, which significantly diminished in intensity after light irradiation, suggesting the opening of the mitochondrial permeability transition pores (Fig. 6a). Additionally, morphological features for apoptotic cells, such as plasma membrane blebbing and nuclear condensation were also observed when the cells were stained with CellMask Deep Red and Hoechst 33342 (Fig. 6b and c), respectively. The activation of caspase-3/7 was also observed, implying an apoptotic pathway for cells treated with the conjugate upon photoactivation (Fig. 6d). The cell death mechanism of the conjugate was further examined using Annexin V/propidium iodide staining assays. As shown in Fig. 6e, there were very low populations of apoptotic cells (2.89%) in cells treated with the conjugate under the dark condition, which is comparable to untreated cells (1.68%) or cells subjected to light irradiation alone (3.76%). However, the population of apoptotic cells sharply increased to 98.28% after photoirradiation of the **1-RGD**-incubated cells, confirming that apoptosis is the primary cell death pathway induced by the conjugate. All these results highlight the use of *S,S*-tetrazine-bearing iridium(III)-RGD conjugates as photoactivatable reagents for cancer-targeted imaging and therapy.

Conclusions

We developed a new platform for the preparation of a cancer-selective photoactivatable anticancer prodrug with controllable emission and photosensitisation of $^1\text{O}_2$. The prodrug was prepared by conjugation of an iridium(III) *Cl,S*-tetrazine complex with a cancer-targeting cyclic RGD peptide. The resulting conjugate **1-RGD** initially displayed low emission intensity and $^1\text{O}_2$ generation efficiency due to the quenching tetrazine unit. However, upon photoactivation, significant emission enhancement and lifetime extension were observed for the conjugate due to the photodissociation of the *S,S*-tetrazine unit, accompanied by improved $^1\text{O}_2$ generation. The IEDDA cycloaddition reaction of the conjugate with BCN-OH also led to substantial emission enhancement. Importantly, conjugate **1-RGD** demonstrated the highest cellular uptake in U87-MG cells overexpressing integrin $\alpha_v\beta_3$ and exhibited remarkable photoinduced anticancer properties resulting from the synergistic effects of the release of the highly cytotoxic iridium(III) thiocyanate and amide complexes and enhanced $^1\text{O}_2$ photogeneration. We believe that the introduction of a *Cl,S*-tetrazine moiety to transition metal complexes or other molecular scaffolds will be a versatile paradigm for the development of innovative anticancer agents or drug delivery systems.

Author contributions

L. H.: conceptualisation, data curation, formal analysis, investigation, writing – original draft, writing – review & editing; J. S.:

data curation, formal analysis, writing – original draft, writing – review & editing; L. C.-C. L.: data curation, formal analysis, writing – original draft, writing – review & editing; G.-X. Xu.: data curation, formal analysis, writing – original draft, writing – review & editing; P. K.-K. L.: data curation, formal analysis, writing – original draft, writing – review & editing; K. K.-W. L.: conceptualisation, funding acquisition, project administration, resources, supervision, writing – original draft, writing – review & editing.

Data availability

The data supporting this article have been included as part of the ESI.†

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank the Hong Kong Research Grants Council (Project No. CityU 11301121, CityU 11317022, CityU 11309423 and C7075-21GF) and the Hong Kong Research Grants Council and National Natural Science Foundation of China (Project No. N_CityU104/21) for financial support. We also thank the funding support from “Laboratory for Synthetic Chemistry and Chemical Biology” under the Health@InnoHK Programme launched by the Innovation and Technology Commission, The Government of Hong Kong SAR, P. R. China. L. H. acknowledges the receipt of a Postgraduate Studentship and Research Tuition Scholarship, both administered by City University of Hong Kong.

References

- J. L. Lau and M. K. Dunn, *Bioorg. Med. Chem.*, 2018, **26**, 2700.
- R. A. Petros and J. M. DeSimone, *Nat. Rev. Drug Discovery*, 2010, **9**, 615.
- R.-M. Lu, Y.-C. Hwang, I. J. Liu, C.-C. Lee, H.-Z. Tsai, H.-J. Li and H.-C. Wu, *J. Biomed. Sci.*, 2020, **27**, 1.
- Y. T. Lee, Y. J. Tan and C. E. Oon, *Eur. J. Pharmacol.*, 2018, **834**, 188.
- E. Pérez-Herrero and A. Fernández-Medarde, *Eur. J. Pharm. Biopharm.*, 2015, **93**, 52.
- Y. Li, K. Xiao, W. Zhu, W. Deng and K. S. Lam, *Adv. Drug Delivery Rev.*, 2014, **66**, 58.
- M. Karimi, A. Ghasemi, P. Sahandi Zangabad, R. Rahighi, S. M. Moosavi Basri, H. Mirshekari, M. Amiri, Z. Shafaei Pishabad, A. Aslani, M. Bozorgomid, D. Ghosh, A. Beyzavi, A. Vaseghi, A. R. Aref, L. Haghani, S. Bahrami and M. R. Hamblin, *Chem. Soc. Rev.*, 2016, **45**, 1457.
- J. M. Silva, E. Silva and R. L. Reis, *J. Controlled Release*, 2019, **298**, 154.
- R. Weinstain, T. Slanina, D. Kand and P. Klán, *Chem. Rev.*, 2020, **120**, 13135.



- 10 X. Ai, J. Mu and B. Xing, *Theranostics*, 2016, **6**, 2439.
- 11 N. A. Smith and P. J. Sadler, *Philos. Trans. R. Soc., A*, 2013, **371**, 20120519.
- 12 K. K.-W. Lo, *Acc. Chem. Res.*, 2015, **48**, 2985.
- 13 C. Imberti, P. Zhang, H. Huang and P. J. Sadler, *Angew. Chem., Int. Ed.*, 2020, **59**, 61.
- 14 L. C.-C. Lee and K. K.-W. Lo, *Chem. Rev.*, 2024, **124**, 8825.
- 15 N. J. Farrer, L. Salassa and P. J. Sadler, *Dalton Trans.*, 2009, 10690.
- 16 U. Schatzschneider, *Eur. J. Inorg. Chem.*, 2010, **2010**, 1451.
- 17 B. S. Howerton, D. K. Heidary and E. C. Glazer, *J. Am. Chem. Soc.*, 2012, **134**, 8324.
- 18 L. N. Lameijer, D. Ernst, S. L. Hopkins, M. S. Meijer, S. H. C. Askes, S. E. Le Dévédec and S. Bonnet, *Angew. Chem., Int. Ed.*, 2017, **56**, 11549.
- 19 K. K.-S. Tso, K.-K. Leung, H.-W. Liu and K. K.-W. Lo, *Chem. Commun.*, 2016, **52**, 4557.
- 20 N. K. Devaraj, S. Hilderbrand, R. Upadhyay, R. Mazitschek and R. Weissleder, *Angew. Chem., Int. Ed.*, 2010, **49**, 2869.
- 21 K. Lang, L. Davis, J. Torres-Kolbus, C. Chou, A. Deiters and J. W. Chin, *Nat. Chem.*, 2012, **4**, 298.
- 22 S. P.-Y. Li, A. M.-H. Yip, H.-W. Liu and K. K.-W. Lo, *Biomaterials*, 2016, **103**, 305.
- 23 J. Shum, L. C.-C. Lee, M. W.-L. Chiang, Y.-W. Lam and K. K.-W. Lo, *Angew. Chem., Int. Ed.*, 2023, **62**, e202303931.
- 24 M. J. Tucker, M. Abdo, J. R. Courter, J. Chen, A. B. Smith III and R. M. Hochstrasser, *J. Photochem. Photobiol., A*, 2012, **234**, 156.
- 25 M. J. Tucker, J. R. Courter, J. Chen, O. Atasoylu, A. B. Smith III and R. M. Hochstrasser, *Angew. Chem., Int. Ed.*, 2010, **49**, 3612.
- 26 J. Waluk, J. Spanget-Larsen and E. W. Thulstrup, *Chem. Phys.*, 1995, **200**, 201.
- 27 C. Canovas, M. Moreau, C. Bernhard, A. Oudot, M. Guillemin, F. Denat and V. Goncalves, *Angew. Chem., Int. Ed.*, 2018, **57**, 10646.
- 28 S. P.-Y. Li, V. M.-W. Yim, J. Shum and K. K.-W. Lo, *Dalton Trans.*, 2019, **48**, 9692.
- 29 J.-H. Zhu, G.-X. Xu, J. Shum, L. C.-C. Lee and K. K.-W. Lo, *Chem. Commun.*, 2021, **57**, 12008.
- 30 K. Suzuki, A. Kobayashi, S. Kaneko, K. Takehira, T. Yoshihara, H. Ishida, Y. Shiina, S. Oishi and S. Tobita, *Phys. Chem. Chem. Phys.*, 2009, **11**, 9850.
- 31 S. Hehlhgans, M. Haase and N. Cordes, *Biochim. Biophys. Acta*, 2007, **1775**, 163.
- 32 E. Ruoslahti and M. D. Pierschbacher, *Science*, 1987, **238**, 491.
- 33 A. Meyer, J. Auernheimer, A. Modlinger and H. Kessler, *Curr. Pharm. Des.*, 2006, **12**, 2723.
- 34 H. Hamidi and J. Ivaska, *Nat. Rev. Cancer*, 2018, **18**, 533.
- 35 S. L. Goodman, H. J. Grote and C. Wilm, *Biol. Open*, 2012, **1**, 329.
- 36 H. A. Kim, K. Nam and S. W. Kim, *Biomaterials*, 2014, **35**, 7543.
- 37 D. Ding, J. Liang, H. Shi, R. T. K. Kwok, M. Gao, G. Feng, Y. Yuan, B. Z. Tang and B. Liu, *J. Mater. Chem. B*, 2014, **2**, 231.
- 38 Z. Zhao, K. Qiu, J. Liu, X. Hao and J. Wang, *Chem. Commun.*, 2020, **56**, 12542.
- 39 S. P.-Y. Li, C. T.-S. Lau, M.-W. Louie, Y.-W. Lam, S. H. Cheng and K. K.-W. Lo, *Biomaterials*, 2013, **34**, 7519.
- 40 C. Caporale and M. Massi, *Coord. Chem. Rev.*, 2018 **363**, 71.
- 41 N. Joza, S. A. Susin, E. Daugas, W. L. Stanford, S. K. Cho, C. Y. J. Li, T. Sasaki, A. J. Elia, H.-Y. M. Cheng, L. Ravagnan, K. F. Ferri, N. Zamzami, A. Wakeham, R. Hakem, H. Yoshida, Y.-Y. Kong, T. W. Mak, J. C. Zúñiga-Pflücker, G. Kroemer and J. M. Penninger, *Nature*, 2001, **410**, 549.
- 42 E. Verdin, M. D. Hirschey, L. W. S. Finley and M. C. Haigis, *Trends Biochem. Sci.*, 2010, **35**, 669.

